Sofie Isebaert

Dr. Sofie Isebaert


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
CDCédric Draulans
Cédric Draulans
UHUulke A. van der Heide
Uulke A. van der Heide
KHKarin Haustermans
Karin Haustermans
FPFloris J. Pos
Floris J. Pos
JZJochem van der Voort van Zyp
Jochem van der Voort van Zyp
LKLinda G.W. Kerkmeijer
Linda G.W. Kerkmeijer

Verified
Journal Article
Open access
PDF file
EBEva Bogaerts
Eva Bogaerts
EMEllina Macaeva
Ellina Macaeva
SISofie Isebaert
Sofie Isebaert
KHKarin Haustermans
Karin Haustermans
FLASH radiotherapy, or the delivery of a dose at an ultra-high dose rate (>40 Gy/s), has recently emerged as a promising tool to enhance the therapeutic index in cancer treatment. The remarkable sparing of normal tissues and equivalent tumor control by FLASH irradiation compared to conventional dose rate irradiation—the FLASH effect—has already been demonstrated in several preclinical models and even in a first patient with T-cell cutaneous lymphoma. However, the biological mechanisms responsible for the differential effect produced by FLASH irradiation in normal and cancer cells remain to be elucidated. This is of great importance because a good understanding of the underlying radiobiological mechanisms and characterization of the specific beam parameters is required for a successful clinical translation of FLASH radiotherapy. In this review, we summarize the FLASH investigations performed so far and critically evaluate the current hypotheses explaining the FLASH effect, including oxygen depletion, the production of reactive oxygen species, and an altered immune response. We also propose a new theory that assumes an important role of mitochondria in mediating the normal tissue and tumor response to FLASH dose rates.


Verified
Journal Article
Open access
PDF file
AGAnnelies Gonnissen
Annelies Gonnissen
SISofie Isebaert
Sofie Isebaert
CMChad M. McKee
Chad M. McKee
RMRuth J. Muschel
Ruth J. Muschel
KHKarin Haustermans
Karin Haustermans
The anti-diabetes drug metformin has been shown to have anti-neoplastic effects in several tumor models through its effects on energy metabolism and protein synthesis. Recent studies show that metformin also targets Hedgehog (Hh) signaling, a developmental pathway re-activated in several tumor types, including prostate cancer (PCa). Furthermore, we and others have shown that Hh signaling is an important target for radiosensitization. Here, we evaluated the combination of metformin and the Hh inhibitor GANT61 (GLI-ANTagonist 61) with or without ionizing radiation in three PCa cell lines (PC3, DU145, 22Rv1). The effect on proliferation, radiosensitivity, apoptosis, cell cycle distribution, reactive oxygen species production, DNA repair, gene and protein expression was investigated. Furthermore, this treatment combination was also assessed in vivo. Metformin was shown to interact with Hh signaling by inhibiting the effector protein glioma-associated oncogene homolog 1 (GLI1) in PCa cells both in vitro and in vivo. The combination of metformin and GANT61 significantly inhibited PCa cell growth in vitro and enhanced the radiation response of 22Rv1 cells compared to either single agent. Nevertheless, neither the growth inhibitory effect nor the radiosensitization effect of the combination treatment observed in vitro was seen in vivo. Although the interaction between metformin and Hh signaling seems to be promising from a therapeutic point of view in vitro, more research is needed when implementing this combination strategy in vivo.

1 November 2019 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
PDF file
CDCédric Draulans
Cédric Draulans
RRRobin De Roover
Robin De Roover
UHUulke A. van der Heide
Uulke A. van der Heide
KHKarin Haustermans
Karin Haustermans
FPFloris Pos
Floris Pos
LKLinda Kerkmeijer
Linda Kerkmeijer

1 March 2018 in The American Journal of Pathology
Verified
Journal Article
Closed access
AGAnnelies Gonnissen
Annelies Gonnissen
SISofie Isebaert
Sofie Isebaert
CPChristiaan Perneel
Christiaan Perneel
CMChad M. McKee
Chad M. McKee
FUFilip Van Utterbeeck
Filip Van Utterbeeck
KHKarin Haustermans
Karin Haustermans